Tenofovir as a treatment option for multiple sclerosis
Copyright © 2020 Elsevier B.V. All rights reserved..
Some antiretroviral medications are also inhibitors of EBV. We describe a patient with highly active MS who was infected with HIV and started HIV-treatment containing tenofovir alafenamide (TAF), a potent inhibitor of EBV lytic reactivation. Her MS was in complete remission during this treatment, and she had new radiological disease activity again after switching to tenofovir disoproxil fumarate, a HIV drug with less potent activity against EBV replication. Based on the recently detected mechanism of TDF and TAF, we suggest that further studies on these drugs in MS are warranted.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:46 |
|---|---|
| Enthalten in: |
Multiple sclerosis and related disorders - 46(2020) vom: 15. Nov., Seite 102569 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Torkildsen, Øivind [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
99YXE507IL |
|---|
| Anmerkungen: |
Date Completed 14.05.2021 Date Revised 14.05.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.msard.2020.102569 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM316191191 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM316191191 | ||
| 003 | DE-627 | ||
| 005 | 20231225160540.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.msard.2020.102569 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1053.xml |
| 035 | |a (DE-627)NLM316191191 | ||
| 035 | |a (NLM)33049462 | ||
| 035 | |a (PII)S2211-0348(20)30643-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Torkildsen, Øivind |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Tenofovir as a treatment option for multiple sclerosis |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.05.2021 | ||
| 500 | |a Date Revised 14.05.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier B.V. All rights reserved. | ||
| 520 | |a Some antiretroviral medications are also inhibitors of EBV. We describe a patient with highly active MS who was infected with HIV and started HIV-treatment containing tenofovir alafenamide (TAF), a potent inhibitor of EBV lytic reactivation. Her MS was in complete remission during this treatment, and she had new radiological disease activity again after switching to tenofovir disoproxil fumarate, a HIV drug with less potent activity against EBV replication. Based on the recently detected mechanism of TDF and TAF, we suggest that further studies on these drugs in MS are warranted | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Autoimmune diseases | |
| 650 | 4 | |a Hiv | |
| 650 | 4 | |a Multiple sclerosis | |
| 650 | 7 | |a Anti-HIV Agents |2 NLM | |
| 650 | 7 | |a Tenofovir |2 NLM | |
| 650 | 7 | |a 99YXE507IL |2 NLM | |
| 700 | 1 | |a Myhr, Kjell-Morten |e verfasserin |4 aut | |
| 700 | 1 | |a Skogen, Vegard |e verfasserin |4 aut | |
| 700 | 1 | |a Steffensen, Linn Hofsøy |e verfasserin |4 aut | |
| 700 | 1 | |a Bjørnevik, Kjetil |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Multiple sclerosis and related disorders |d 2012 |g 46(2020) vom: 15. Nov., Seite 102569 |w (DE-627)NLM219118388 |x 2211-0356 |7 nnns |
| 773 | 1 | 8 | |g volume:46 |g year:2020 |g day:15 |g month:11 |g pages:102569 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.msard.2020.102569 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 46 |j 2020 |b 15 |c 11 |h 102569 | ||